Overview

This trial is active, not recruiting.

Conditions pleural effusion, pleural effusion malignant
Treatments naproxen, placebo
Phase phase 2
Sponsor McMaster University
Collaborator McMaster Surgical Associates
Start date April 2014
End date October 2016
Trial size 300 participants
Trial identifier NCT01612975, SJHHNaproxenRCT

Summary

Following a lung resection procedure, patients have their pleural space drained of fluid that accumulates due to the severing of proximal vessels like lymph nodes. The volume of fluid pumped depends on the severity of the inflammation. The investigators are conduction this study to attempt to use painkillers with intrinsic anti-inflammatory action to try and reduce the degree of inflammation in patients' pleural cavity, thus ensuring patients are discharged faster, with a greater comfort level, and a hopefully lower rate of admission.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, investigator)
Primary purpose treatment
Arm
(Placebo Comparator)
This study arm will encompass the administration of a placebo (physically identical to Naproxen) orally to participants. Naproxen is a painkiller with intrinsic anti-inflammatory properties, while the placebo has no pharmacological properties associated with it. Participants will also be taking Pantoprazole to negate the gastrointestinal consequences of Naproxen (or the placebo). Participants will not know which arm of the study they belong to. In addition, they will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety.
placebo
Inert, inactive placebo pill similar in appearance to naproxen allocation. To be taken twice daily for 4 weeks total along with 40mg pantoprazole.
(Experimental)
Intervention arm involves administering 500mg Naproxen twice a day to participants and 40mg of Pantoprazole once a day in tandem. Pantoprazole will negate gastrointestinal consequences of Naproxen and reduce the likelihood of a complication occurring. Participants will take Naproxen at the above dosage from the time of surgery to four weeks following surgery. They will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety. This experiment is double-blinded so neither investigators nor participants will know which arm of the study they belong to.
naproxen
Intervention arm involves administering 500mg Naproxen BID to participants and 40mg of Pantoprazole in tandem. Pantoprazole will negate gastrointestinal consequences of Naproxen and reduce the likelihood of a complication occurring. Participants will take Naproxen at the above dosage from the time of surgery to four weeks following surgery. They will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety. This experiment is double-blinded so neither investigators nor participants will know which arm of the study they belong to.

Primary Outcomes

Measure
Change in volume of pleural effusion collected
time frame: 4 weeks

Secondary Outcomes

Measure
Hospital length of stay; compared between intervention and control arms
time frame: 4 weeks
Gastrointestinal complications
time frame: 4 weeks
General re-admission rates
time frame: 4 weeks
Total number of days chest tubes remain in-situ
time frame: 4 weeks

Eligibility Criteria

Male or female participants from 18 years up to 100 years old.

Inclusion Criteria: - Participants must be 18 years of age or older - Participants must be undergoing a major lung resection due to primary or secondary malignancy - Must have an aptitude for following directions and commitment to the study Exclusion Criteria: - Patients who are unable to read and communicate in English - Patients undergoing a pneumonectomy or Open lung resection - Previous treatments on the same anatomical side including chemotherapy, radiation therapy, and radio-frequency ablation - Patients who have undergone decortication for empyema or malignancy. - Patients who have a chest tube in-situ for persistent air leak - Patients with clinical or laboratory indicators of renal failure, defined as serum creatinine level of 170µmol/l - Patients with active or previous history of peptic ulcer disease - Patients with a known intolerance to Proton Pump Inhibitors (PPIs) - Known allergy to study drugs - Use of NSAIDs 4 weeks prior to randomization or on-going use of NSAIDs. - The use of any medications known to reduce inflammation, including but not limited to: steroids (both oral and intravenously), methotrexate, COX-II inhibitors, other NSAIDs - Chest tube for persistent air leak. - Patients who are pregnant or lactating - Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. - Inability or unwillingness of individual or legal guardian/representative to give written informed consent

Additional Information

Official title The Effect of Perioperative Non-Steroidal Anti-Inflammatory Drug Naproxen on Pleural Effusion Formation After Lung Resection
Principal investigator Yaron Shargall, MD, BSc, FRCSC
Description In this study the investigators will attempt to reduce the degree of inflammation (and thus polymorphonuclear leukocyte counts) in the pleural space following a lung resection procedure by administering the Non Steroid Anti-Inflammatory Drug (NSAID) Naproxen in tandem with Proton Pump Inhibitor (PPI) Pantoprazole, ideally leading towards a significantly reduced volume of transudate and exudate generated. This will be achieved by running a placebo-controlled double blinded randomized control trial where investigators and participants will be blinded so as to eliminate experimenter bias. After screening for suitable participants using stringent inclusion and exclusion criteria, patients will be administered by allied health professionals 500mg Naproxen twice daily and 40mg Pantoprazole once daily, or an identical placebo for four weeks following resection surgery. Patients will undergo a thorough examination during their scheduled follow-up appointments to monitor general vitals as well as possible gastrointestinal complications. The primary outcome is a significant reduction (Δ100ml) of chest fluid extracted in the intervention arm of the study in comparison to that of the control arm. Secondary outcomes will include a reduction in length of stay measured in days between control and intervention arms as well as a reduction in the total number of days chest tubes are retained in-situ. Conditions such as mortality and morbidity, the onset of complications, and general re-admission rates will also be recorded.
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by McMaster University.